Fate Therapeutics (FATE) vs Nautilus Biotechnology (NAUT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nautilus Biotechnology (NAUT) has outperformed Fate Therapeutics (FATE) over the past year, gaining 126.3% versus a gain of 54.7%. Over five years, NAUT leads with a -65.7% price change compared with -96.5% for FATE. Fate Therapeutics is the larger company by market cap ($257.6 million vs $249.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FATE | NAUT |
|---|---|---|
| Share price | $2.15 | $1.96 |
| Market cap | $257.61M | $249.42M |
| 1-day change | -6.11% | +10.73% |
| YTD return | +119.39% | +0.51% |
| 1-year return | +54.68% | +126.33% |
| 5-year return | -96.49% | -65.67% |
| EPS (TTM) | $-1.05 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.23 | $4.31 |
| 52-week low | $0.95 | $0.82 |
| Distance from 52-week high | -33.44% | -54.52% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +166.98% | +95.41% |
| Average volume | 1.90M | 2.43M |
| Shares outstanding | 119.82M | 127.26M |
| Employees | 161 | 127 |
| Sector | Health Care | Industrials |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NAUT has outperformed FATE by 71.7 percentage points over the past year.
- The two companies sit in different sectors: Fate Therapeutics in Health Care and Nautilus Biotechnology in Industrials.
About Fate Therapeutics
FATE stock →Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees
About Nautilus Biotechnology
NAUT stock →Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Industrials · Biotechnology: Laboratory Analytical Instruments · 127 employees
FATE vs NAUT FAQ
Which is bigger, Fate Therapeutics or Nautilus Biotechnology?
Fate Therapeutics (FATE) is larger, with a market capitalization of $257.61M compared with $249.42M for Nautilus Biotechnology (NAUT).
Which stock has performed better over the past year, FATE or NAUT?
NAUT returned +126.33% over the past 12 months, compared with +54.68% for FATE (price return, excluding dividends). Past performance does not predict future results.
Are Fate Therapeutics and Nautilus Biotechnology in the same industry?
No. Fate Therapeutics is in the Health Care sector, while Nautilus Biotechnology is in Industrials.